

Prescriber Criteria Form

Mektovi 2025 PA Fax 2613-A v1 010125.docx  
Mektovi (binimetinib)  
Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673**. Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Mektovi (binimetinib).

Drug Name:  
Mektovi (binimetinib)

|                            |                        |             |
|----------------------------|------------------------|-------------|
| <b>Patient Name:</b>       |                        |             |
| <b>Patient ID:</b>         |                        |             |
| <b>Patient DOB:</b>        | <b>Patient Phone:</b>  |             |
| <b>Prescriber Name:</b>    |                        |             |
| <b>Prescriber Address:</b> |                        |             |
| <b>City:</b>               | <b>State:</b>          | <b>Zip:</b> |
| <b>Prescriber Phone:</b>   | <b>Prescriber Fax:</b> |             |
| <b>Diagnosis:</b>          | <b>ICD Code(s):</b>    |             |

| <b>Please circle the appropriate answer for each question.</b> |   |     |    |
|--|---|-----|----|
| 1  | Does the patient have a diagnosis of melanoma?<br>[If no, then skip to question 6.]   | Yes | No |
| 2  | Is the requested drug being used for adjuvant systemic therapy?<br>[If yes, then skip to question 4.]   | Yes | No |
| 3  | Is the disease unresectable, limited resectable, or metastatic?<br>[If no, then no further questions.]  | Yes | No |
| 4  | Does the patient have disease that is positive for BRAF V600 activating mutation (e.g., V600E or V600K)?<br>[If no, then no further questions.] | Yes | No |
| 5  | Will the requested drug be used in combination with encorafenib?<br>[No further questions.]   | Yes | No |
| 6  | Does the patient have a diagnosis of Langerhans Cell Histiocytosis?<br>[If yes, then no further questions.]                                     | Yes | No |
| 7  | Does the patient have a diagnosis of non-small cell lung cancer (NSCLC)?<br>[If no, then no further questions.]                                 | Yes | No |

|    |   |     |    |
|----|---|-----|----|
| 8  | Is the disease advanced, recurrent, or metastatic?<br>[If no, then no further questions.] | Yes | No |
| 9  | Is the tumor positive for BRAF V600E mutation?<br>[If no, then no further questions.]     | Yes | No |
| 10 | Will the requested drug be used in combination with encorafenib?                          | Yes | No |

|           |  |
|-----------|--|
| Comments: |  |
|-----------|--|

By signing this form, I attest that the information provided is accurate and true as of this date and that the documentation supporting this information is available for review if requested by the health plan.

|   |
|---|
| <b>Prescriber (or Authorized) Signature:</b> _____ <b>Date:</b> _____ |
|---|